The DOI matches its Crossref record.
Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2* activities
Abstract
BACKGROUND: The urinary molar concentration ratios of several caffeine metabolites are indicators of specific drug metabolizing enzyme activities. The ratios of 5-acetyl-amino-6-formylamino-3-methyluracil (AFMU) to 1-methylxanthine (1X), AFMU to 1X plus 1-methyluric acid (1U), and AFMU to 1X + 1U + AFMU are indicative of N-acetyltransferase (NAT) activity; the ratios of 1U to 1X and 1U to 1U + 1X indicate xanthine oxidase activity; and the ratio of the sum of 7-demethylated metabolites (AFMU + 1X + 1U) to the precursor for all three compounds, paraxanthine (PX), is a putative indicator of CYP1A2 oxidative activity. Our objective was to discern whether there are race-, gender-, and age-related differences in these indexes of drug-metabolizing activity. METHODS: In 342 normal healthy unrelated subjects, metabolites were measured in urine collected after administration of low-dose caffeine. RESULTS: By two-way analysis of variance, NAT activity was higher in black subjects than in white subjects when assessed as AFMU/(1U + 1X) or as AFMU/(AFMU + 1U + 1X) (p = 0.001 and p = 0.002, respectively), but less so by use of AFMU/1X (p = 0.08). Xanthine oxidase activity, as assessed by 1U/1X or as 1U/(1U + 1X), was lower in black subjects than in white subjects (p = 0.02 and p = 0.001, respectively) and was lower in males than in females (p = 0.001 for both ratios). Females had higher AFMU/1X ratios (p = 0.03) because of higher xanthine oxidase activity. In a model in which AFMU/1X was the dependent variable and race, sex, age, and an index of xanthine oxidase (1U/1X) were independent variables, only race and 1U/1X were significant determinants of this NAT index (p = 0.003 and p < 0.001, respectively). The CYP1A2 ratio was lower in black subjects (p = 0.036) and in females (p = 0.015). CONCLUSION: Racial and gender differences in xanthine oxidase activity render the AFMU/1X ratio less reliable as an assessment of NAT activity in a heterogeneous population compared with the AFMU/(1U + 1X) or AFMU/(AFMU + 1U + 1X) ratios. The observed racial and gender differences in NAT, xanthine oxidase, and CYP1A2 activities may have implications for racial and gender differences in drug effects and carcinogen biotransformation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
“CYP1A2 activity in vivo was reported to be higher in men than in women for several substrates including the conversion of caffeine to paraxanthine (Relling et al., 1992; Ou-Yang et al., 2000).”
BackgroundSex Differences in Pharmacokinetics and Pharmacodynamics
Soldin, O. P., & Mattison, D. R. (2009) · Clinical Pharmacokinetics · doi:10.2165/00003088-200948030-00001 · Cited by 1,163
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S.-F., Liu, J.-P., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 826
Gender Effects in Pharmacokinetics and Pharmacodynamics
Harris, R. Z., Benet, L. Z., & Schwartz, J. B. (1995) · Drugs · doi:10.2165/00003495-199550020-00003 · Cited by 506
The Influence of Sex on Pharmacokinetics
Schwartz, J. B. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342020-00001 · Cited by 467
How Important Are Gender Differences in Pharmacokinetics?
Meibohm, B., Beierle, I., & Derendorf, H. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241050-00002 · Cited by 454
Streetman, D. S., Bertino, J. S., & Nafziger, A. N. (2000) · Pharmacogenetics · doi:10.1097/00008571-200004000-00001 · Cited by 425
Clinically Significant Pharmacokinetic Interactions Between Dietary Caffeine and Medications
Carrillo, J. A., & Benitez, J. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200039020-00004 · Cited by 364
Gurney, H. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.9.2590 · Cited by 361
The neuroprotective effects of caffeine: A prospective population study (the Three City Study)
Ritchie, K., Carrière, I., de Mendonça, A., Portet, F., Dartigues, J. F., Rouaud, O., Barberger-Gateau, P., & Ancelin, M. L. (2007) · Neurology · doi:10.1212/01.wnl.0000266670.35219.0c · Cited by 347
Aldehyde Oxidase: An Enzyme of Emerging Importance in Drug Discovery
Pryde, D. C., Dalvie, D., Hu, Q., Jones, P., Obach, R. S., & Tran, T.-D. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100888d · Cited by 345
Anderson, G. D. (2005) · Journal of Women's Health · doi:10.1089/jwh.2005.14.19 · Cited by 321
Gender-related differences in pharmacokinetics and their clinical significance
Tanaka, E. (1999) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.1999.00246.x · Cited by 281
Rostami-Hodjegan, A., Amin, A. M., Spencer, E. P., Lennard, M. S., Tucker, G. T., & Flanagan, R. J. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000106221.36344.4d · Cited by 278
Recent Advances: the Cytochrome P450 Enzymes
Slaughter, R. L., & Edwards, D. J. (1995) · Annals of Pharmacotherapy · doi:10.1177/106002809502900612 · Cited by 274
Zhou, S.-F., Wang, B., Yang, L.-P., & Liu, J.-P. (2010) · Drug Metabolism Reviews · doi:10.3109/03602530903286476 · Cited by 262
Gunes, A., & Dahl, M.-L. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.5.625 · Cited by 256
The Current State of Knowledge on Age, Sex, and Their Interactions on Clinical Pharmacology
Schwartz, J. B. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100226 · Cited by 256
Sturgill, M. G., & Lambert, G. H. (1997) · Clinical Chemistry · doi:10.1093/clinchem/43.8.1512 · Cited by 252
Drug-Metabolizing Ability of Molybdenum Hydroxylases
Kitamura, S., Sugihara, K., & Ohta, S. (2006) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.21.83 · Cited by 216
Maier (2005) · doi:10.1016/j.neubiorev.2004.08.001 · Cited by 216
Sex-specific differences in CYP450 isoforms in humans
Scandlyn, M. J., Stuart, E. C., & Rosengren, R. J. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.4.413 · Cited by 199
The role of aldehyde oxidase in drug metabolism
Garattini, E., & Terao, M. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.663352 · Cited by 174
Coffee Consumption and Cognitive Function among Older Adults
Johnson-Kozlow, M. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf119 · Cited by 173
Genetic Polymorphism in N-Acetyltransferase (NAT): Population Distribution of NAT1 and NAT2 Activity
Walker, K., Ginsberg, G., Hattis, D., Johns, D. O., Guyton, K. Z., & Sonawane, B. (2009) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937400903158383 · Cited by 140
Fluoxetine Pharmacokinetics in Pediatric Patients
Wilens, T. E., Cohen, L., Biederman, J., Abrams, A., Neft, D., Faird, N., & Sinha, V. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200212000-00006 · Cited by 64
Biological sex differences in pharmacokinetics and adverse drug reactions
Aljohmani, A., & Yildiz, D. (2026) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-025-04721-8 · Cited by 35
Effect of Abrupt Discontinuation of Antidepressants in Critically Ill Hospitalized Adults
Bainum, T. B., Fike, D. S., Mechelay, D., & Haase, K. K. (2017) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1992 · Cited by 28
Cosson, V., Schaedeli‐Stark, F., Arab‐Alameddine, M., Chavanne, C., Guerini, E., Derks, M., & Mallalieu, N. L. (2018) · Clinical and Translational Science · doi:10.1111/cts.12566 · Cited by 7
Metadata
- Authors
- Relling, M. V., Lin, J.-S., Ayers, G. D., & Evans, W. E.
- Venue
- Clinical Pharmacology and Therapeutics
- Publisher
- Wiley
- Published
- 1992-12
- Volume
- 52
- Issue
- 6
- Pages
- 643-658
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2035776430
- Cited by
- 314
- References
- 0
- FWCI
- 9.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.